Glioblastoma trial design is expanding and becoming more suited to clinical practice
Researchers at the University of Tsukuba have investigated the changes in the primary evaluation items in phase II clinical ...
Skye Bioscience accelerates nimacimab clinical trial timeline with early enrollment and extended treatment period
Discover Skye Bioscience's progress on nimacimab with early trial enrollment, extended treatment protocols, and robust regulatory plans.
Fierce Pharma7h
Novartis snags FDA nod for Fabhalta in another kidney disease but leaves room for rival Apellis
Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...
Healio7h
Tremfya’s FDA win as fully subcutaneous option for Crohn’s may pave way to eclipse Stelara
The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...
The American Journal of Managed Care8h
FDA Approves Oral Iptacopan for C3 Glomerulopathy
The FDA approved oral iptacopan (Fabhalta; Novartis) to reduce proteinuria in adults with C3 glomerulopathy (C3G), according ...
MPR7h
Fabhalta Approved as First Treatment for C3 Glomerulopathy
The approval of iptacopan in reducing proteinuria in adult patients with native kidney C3G was based on data from the randomized, double-blind, placebo-controlled, phase 3 APPEAR-C3G trial.
Novartis21h
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...
pharmaphorum22h
Chasing Novartis, Amgen ushers Lp(a) drug into phase 3
It is playing catch-up with a rival Lp(a) targeting antisense drug from Novartis and development partner Akcea, called pelacarsen, which is already in a phase 3 trial called HORIZON with major ...